Looks like the Medical Community is finally catching up with the patient community; i.e.:
"I think the key result of this study is that sequencing testosterone and then anti-testosterone therapy, in this case enzalutamide, seems to be the ideal way [to modify the adaptive process]," Denmeade told MedPage Today. "A tumor seems to be sensitive and then adapts and becomes insensitive, so you switch treatments."
* * *
"We're at a point where we're trying to understand the best way to use this treatment," said Denmeade. "We're still working on how to incorporate testosterone into the treatment paradigm. We think it has the potential to augment and extend the response."
medpagetoday.com/hematology...
SOC part deux? Stay Tuned - and also Safe & Well - K9 terror